What are the guidelines for carotid artery intervention in carotid artery disease?

Guidelines for Carotid Artery Intervention in Carotid Artery Disease

For symptomatic carotid stenosis ≥50%, carotid endarterectomy (CEA) should be performed within 48 hours to 14 days after the ischemic event, with intervention strongly recommended for stenosis ≥70% and suggested for 50-69% stenosis 1, 2, 3, 4.

Symptomatic Carotid Stenosis

Degree of Stenosis and Intervention Thresholds

Severe stenosis (≥70%):

• CEA is strongly recommended as first-line treatment 3, 4
• Perioperative stroke/death risk must be <3% to ensure benefit 3, 5
• Carotid artery stenting (CAS) may be considered in patients <70 years old 4

Moderate stenosis (50-69%):

• CEA is suggested but with less certainty than for severe stenosis 3, 4
• All guidelines recommend revascularization for at least a subgroup of these patients 6

Mild stenosis (<50%):

• Revascularization generally not recommended 6
• Two guidelines suggest considering intervention only when refractory to optimal medical therapy 6

Critical Timing Considerations

The window for intervention is narrow and evidence-based:

• Perform revascularization as soon as neurologically stable after 48 hours 3
• Must complete intervention within 14 days of symptom onset 1, 3
• Earlier intervention (within 2 weeks) significantly reduces recurrent stroke risk 4

This timing recommendation represents high-quality evidence and is consistent across multiple guidelines. Delaying beyond 14 days substantially diminishes the benefit of intervention.

Asymptomatic Carotid Stenosis

For asymptomatic stenosis ≥70%, CEA can be considered if life expectancy is 3-5 years and perioperative stroke/death risk is <3% 3, 5.

Selection Criteria for Intervention

The decision requires careful risk stratification:

• Patient must have ≥70% stenosis documented by imaging 3, 5, 4
• Life expectancy must be 3-5 years minimum 3, 5
• Institutional perioperative stroke/death rate must be <3% 3, 5
• Consider clinical or morphological markers indicating increased stroke risk 2, 7

Important caveat: The evidence supporting intervention in asymptomatic patients is moderate quality at best 4. Most randomized trials supporting CEA for asymptomatic disease were conducted decades ago, before modern intensive medical therapy became standard 4. The 2025 ESC consensus emphasizes that triple medical therapy (antiplatelet, antihypertensive, and intensive LDL-lowering) substantially reduces stroke risk and may alter the risk-benefit calculation 2.

Choice of Revascularization Technique

CEA vs. CAS Decision Algorithm

CEA is recommended as first-line for:

• Low surgical risk patients with symptomatic stenosis ≥50% 3
• Asymptomatic patients ≥70% stenosis meeting intervention criteria 3, 5

CAS may be considered for:

• Patients <70 years old with symptomatic stenosis ≥50% 4
• High surgical risk patients (though evidence is limited) 7
• Patients requiring transcarotid artery revascularization (TCAR) as an alternative 5

The 2022 SVS guidelines note that properly selected asymptomatic patients can be treated with CAS with equivalent outcomes to CEA when performed by experienced operators meeting AHA standards 5. However, the European Stroke Organisation guideline (2021) provides only low-quality evidence for CAS in younger symptomatic patients 4.

Mandatory Medical Management

All patients with carotid artery disease must receive intensive triple medical therapy regardless of whether they undergo revascularization 2.

Specific Medical Therapy Components

Lipid management:

• Intensive statin therapy targeting LDL-C <55 mg/dL 2
• Add ezetimibe or PCSK9 inhibitor if target not achieved 2
• PCSK9 inhibitors (evolocumab) reduced ischemic stroke by 25% in trials 2

Antiplatelet therapy for symptomatic patients:

• Acute phase (first 90 days): Ticagrelor monotherapy is superior to aspirin for patients with ipsilateral atherosclerotic stenosis (HR 0.68, P=0.003) 2
• Post-CEA: Continue single antiplatelet (aspirin or clopidogrel) for 1-3 months 2
• Post-CAS: Dual antiplatelet therapy (DAPT) with clopidogrel loading pre-procedure, continue DAPT for 1-3 months (4-6 weeks for single-layer stents, up to 3 months for mesh stents), then switch to single agent 2

Antihypertensive therapy:

• Goal-directed blood pressure control per secondary prevention guidelines 2

Lifestyle modifications:

• High-quality diet (modified Alternative Healthy Eating Index) reduces stroke by 14% 2
• Smoking cessation, weight loss, regular exercise 2

Special Situations

Combined Carotid and Coronary Disease

For patients requiring both CEA and CABG with symptomatic carotid stenosis 50-99%, perform CEA before or concurrent with CABG 1, 3.

The sequencing depends on clinical presentation:

• Symptomatic carotid disease with stable cardiac disease: CEA first
• Unstable cardiac disease: consider simultaneous procedures if institutional experience supports this
• Asymptomatic severe carotid stenosis before CABG: safety and efficacy not well established 1

Pre-CABG Screening

Screen with carotid duplex ultrasound before elective CABG in:

• Patients >65 years old 1
• Left main coronary stenosis 1
• Peripheral arterial disease 1
• History of smoking, stroke, TIA, or carotid bruit 1

Carotid Dissection

For extracranial carotid dissection with ischemic symptoms:

• Antithrombotic treatment (anticoagulation or antiplatelet) for 3-6 months is reasonable 1
• CAS might be considered if symptoms persist despite antithrombotic therapy 1

Common Pitfalls to Avoid

1. Delaying intervention beyond 14 days in symptomatic patients eliminates much of the benefit
2. Performing CEA in asymptomatic patients at centers with perioperative stroke/death rates >3%
3. Intervening on asymptomatic patients with limited life expectancy (<3-5 years)
4. Failing to provide intensive medical therapy to all patients regardless of intervention status
5. Using outdated antiplatelet regimens when ticagrelor has shown superiority in symptomatic patients with atherosclerotic stenosis 2

Areas of Ongoing Uncertainty

The 2025 systematic review identified important discrepancies between guidelines, particularly for mild and moderate stenosis 6. Only 13% of guidelines incorporate plaque vulnerability assessment into decision-making 6. The role of modern intensive medical therapy may have fundamentally changed the risk-benefit calculation for intervention, especially in asymptomatic disease, as most supporting trials predate current medical management standards 4.